Does ARS Pharmaceuticals Inc (SPRY) Stock Really Excited You?
Leerink Partners raised the price target for the ARS Pharmaceuticals Inc (NASDAQ:SPRY) stock from “a Market perform” to “an Outperform”. The rating was released on March 05, 2024, according to finviz. The stock was initiated by Wedbush, who disclosed in a research note on January 31, 2023, to Outperform and set the price objective to […]
The growth of ARS Pharmaceuticals Inc (SPRY) Stock is expected to continue
Leerink Partners raised the price target for the ARS Pharmaceuticals Inc (NASDAQ:SPRY) stock from “a Market perform” to “an Outperform”. The rating was released on March 05, 2024, according to finviz. The stock was initiated by Wedbush, who disclosed in a research note on January 31, 2023, to Outperform and set the price objective to […]
Why ARS Pharmaceuticals Inc (NASDAQ:SPRY) Stock rose 180.77% in Last Six Months?
Leerink Partners raised the price target for the ARS Pharmaceuticals Inc (NASDAQ:SPRY) stock from “a Market perform” to “an Outperform”. The rating was released on March 05, 2024, according to finviz. The stock was initiated by Wedbush, who disclosed in a research note on January 31, 2023, to Outperform and set the price objective to […]
ARS Pharmaceuticals Inc (SPRY) Stock is the one stock you should own forever
Leerink Partners raised the price target for the ARS Pharmaceuticals Inc (NASDAQ:SPRY) stock from “a Market perform” to “an Outperform”. The rating was released on March 05, 2024, according to finviz. The stock was initiated by Wedbush, who disclosed in a research note on January 31, 2023, to Outperform and set the price objective to […]
Analysts Estimated Revenue of $1M in the current quarter for ARS Pharmaceuticals Inc (NASDAQ:SPRY) Stock
Leerink Partners raised the price target for the ARS Pharmaceuticals Inc (NASDAQ:SPRY) stock from “a Market perform” to “an Outperform”. The rating was released on March 05, 2024, according to finviz. The stock was initiated by Wedbush, who disclosed in a research note on January 31, 2023, to Outperform and set the price objective to […]
ARS Pharmaceuticals Inc (NASDAQ:SPRY) Stock upgraded by Leerink Partners
Leerink Partners raised the price target for the ARS Pharmaceuticals Inc (NASDAQ:SPRY) stock from “a Market perform” to “an Outperform”. The rating was released on March 05, 2024, according to finviz. The stock was initiated by Wedbush, who disclosed in a research note on January 31, 2023, to Outperform and set the price objective to […]